Literature DB >> 33861416

Anesthesia Medications and Interaction with Chemotherapeutic Agents.

Jeremy Watson1, Michael K Ninh1, Scott Ashford1, Elyse M Cornett2, Alan David Kaye3, Ivan Urits4, Omar Viswanath5,6,7,8.   

Abstract

Cancer is now a leading health concern worldwide. In an effort to provide these patients with adequate care, coordination between anesthesiologists and surgeons is crucial. In cancer-related treatment, it is very clear that radio-chemotherapy and medical procedures are important. There are some obstacles to anesthesia when dealing with cancer treatment, such as physiological disturbances, tumor-related symptoms, and toxicity in traditional chemotherapy treatment. Therefore, it is important that a multisystemic, multidisciplinary and patient-centered approach is used to preserve perioperative homeostasis and immune function integrity. Adding adjuvants can help increase patient safety and satisfaction and improve clinical efficacy. Correctly paired anesthetic procedures and medications will reduce perioperative inflammatory and immune changes that could potentially contribute to improved results for future cancer patients. Further research into best practice strategies is required which will help to enhance the acute and long-term effects of cancer care in clinical practice.

Entities:  

Keywords:  Anesthesia; Cancer; Desflurane; Isoflurane; Ketamine; Oncology; Pain; Propofol; Sevoflurane

Year:  2021        PMID: 33861416     DOI: 10.1007/s40487-021-00149-1

Source DB:  PubMed          Journal:  Oncol Ther        ISSN: 2366-1089


  54 in total

Review 1.  Cancer recurrence after surgery: direct and indirect effects of anesthetic agents.

Authors:  Aniket N Tavare; Nicholas J S Perry; Laura L Benzonana; Masao Takata; Daqing Ma
Journal:  Int J Cancer       Date:  2011-11-09       Impact factor: 7.396

Review 2.  Effects of propofol on cancer development and chemotherapy: Potential mechanisms.

Authors:  Sufang Jiang; Ya Liu; Lining Huang; Fuzhen Zhang; Rongtian Kang
Journal:  Eur J Pharmacol       Date:  2018-04-11       Impact factor: 4.432

3.  [Phenol test of Kunkel in atherosclerosis].

Authors:  V A Tikhonravov; L L Gladkova
Journal:  Lab Delo       Date:  1967

4.  Propofol inhibits the growth and survival of gastric cancer cells in vitro through the upregulation of ING3.

Authors:  Cheng Yang; Jie Gao; Nuo Yan; Banglin Wu; Yiqing Ren; Hui Li; Jiamin Liang
Journal:  Oncol Rep       Date:  2016-11-04       Impact factor: 3.906

5.  Volatile anesthetics induce caspase-dependent, mitochondria-mediated apoptosis in human T lymphocytes in vitro.

Authors:  Torsten Loop; David Dovi-Akue; Michael Frick; Martin Roesslein; Lotti Egger; Matjaz Humar; Alexander Hoetzel; Rene Schmidt; Christoph Borner; Heike L Pahl; Klaus K Geiger; Benedikt H J Pannen
Journal:  Anesthesiology       Date:  2005-06       Impact factor: 7.892

6.  Isoflurane, a commonly used volatile anesthetic, enhances renal cancer growth and malignant potential via the hypoxia-inducible factor cellular signaling pathway in vitro.

Authors:  Laura L Benzonana; Nicholas J S Perry; Helena R Watts; Bob Yang; Iain A Perry; Charles Coombes; Masao Takata; Daqing Ma
Journal:  Anesthesiology       Date:  2013-09       Impact factor: 7.892

7.  Suppression of natural killer cell activity and promotion of tumor metastasis by ketamine, thiopental, and halothane, but not by propofol: mediating mechanisms and prophylactic measures.

Authors:  Rivka Melamed; Shahar Bar-Yosef; Guy Shakhar; Keren Shakhar; Shamgar Ben-Eliyahu
Journal:  Anesth Analg       Date:  2003-11       Impact factor: 5.108

8.  Propofol induces apoptosis of breast cancer cells by downregulation of miR-24 signal pathway.

Authors:  Benxia Yu; Wei Gao; Hui Zhou; Xia Miao; Yuan Chang; Liping Wang; Miao Xu; Guangzhen Ni
Journal:  Cancer Biomark       Date:  2018-02-14       Impact factor: 4.388

9.  Propofol suppresses LPS-induced nuclear accumulation of HIF-1α and tumor aggressiveness in non-small cell lung cancer.

Authors:  Nengli Yang; Yafeng Liang; Pei Yang; Fuhai Ji
Journal:  Oncol Rep       Date:  2017-03-17       Impact factor: 3.906

10.  Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016: A Systematic Analysis for the Global Burden of Disease Study.

Authors:  Christina Fitzmaurice; Tomi F Akinyemiju; Faris Hasan Al Lami; Tahiya Alam; Reza Alizadeh-Navaei; Christine Allen; Ubai Alsharif; Nelson Alvis-Guzman; Erfan Amini; Benjamin O Anderson; Olatunde Aremu; Al Artaman; Solomon Weldegebreal Asgedom; Reza Assadi; Tesfay Mehari Atey; Leticia Avila-Burgos; Ashish Awasthi; Huda Omer Ba Saleem; Aleksandra Barac; James R Bennett; Isabela M Bensenor; Nickhill Bhakta; Hermann Brenner; Lucero Cahuana-Hurtado; Carlos A Castañeda-Orjuela; Ferrán Catalá-López; Jee-Young Jasmine Choi; Devasahayam Jesudas Christopher; Sheng-Chia Chung; Maria Paula Curado; Lalit Dandona; Rakhi Dandona; José das Neves; Subhojit Dey; Samath D Dharmaratne; David Teye Doku; Tim R Driscoll; Manisha Dubey; Hedyeh Ebrahimi; Dumessa Edessa; Ziad El-Khatib; Aman Yesuf Endries; Florian Fischer; Lisa M Force; Kyle J Foreman; Solomon Weldemariam Gebrehiwot; Sameer Vali Gopalani; Giuseppe Grosso; Rahul Gupta; Bishal Gyawali; Randah Ribhi Hamadeh; Samer Hamidi; James Harvey; Hamid Yimam Hassen; Roderick J Hay; Simon I Hay; Behzad Heibati; Molla Kahssay Hiluf; Nobuyuki Horita; H Dean Hosgood; Olayinka S Ilesanmi; Kaire Innos; Farhad Islami; Mihajlo B Jakovljevic; Sarah Charlotte Johnson; Jost B Jonas; Amir Kasaeian; Tesfaye Dessale Kassa; Yousef Saleh Khader; Ejaz Ahmad Khan; Gulfaraz Khan; Young-Ho Khang; Mohammad Hossein Khosravi; Jagdish Khubchandani; Jacek A Kopec; G Anil Kumar; Michael Kutz; Deepesh Pravinkumar Lad; Alessandra Lafranconi; Qing Lan; Yirga Legesse; James Leigh; Shai Linn; Raimundas Lunevicius; Azeem Majeed; Reza Malekzadeh; Deborah Carvalho Malta; Lorenzo G Mantovani; Brian J McMahon; Toni Meier; Yohannes Adama Melaku; Mulugeta Melku; Peter Memiah; Walter Mendoza; Tuomo J Meretoja; Haftay Berhane Mezgebe; Ted R Miller; Shafiu Mohammed; Ali H Mokdad; Mahmood Moosazadeh; Paula Moraga; Seyyed Meysam Mousavi; Vinay Nangia; Cuong Tat Nguyen; Vuong Minh Nong; Felix Akpojene Ogbo; Andrew Toyin Olagunju; Mahesh Pa; Eun-Kee Park; Tejas Patel; David M Pereira; Farhad Pishgar; Maarten J Postma; Farshad Pourmalek; Mostafa Qorbani; Anwar Rafay; Salman Rawaf; David Laith Rawaf; Gholamreza Roshandel; Saeid Safiri; Hamideh Salimzadeh; Juan Ramon Sanabria; Milena M Santric Milicevic; Benn Sartorius; Maheswar Satpathy; Sadaf G Sepanlou; Katya Anne Shackelford; Masood Ali Shaikh; Mahdi Sharif-Alhoseini; Jun She; Min-Jeong Shin; Ivy Shiue; Mark G Shrime; Abiy Hiruye Sinke; Mekonnen Sisay; Amber Sligar; Muawiyyah Babale Sufiyan; Bryan L Sykes; Rafael Tabarés-Seisdedos; Gizachew Assefa Tessema; Roman Topor-Madry; Tung Thanh Tran; Bach Xuan Tran; Kingsley Nnanna Ukwaja; Vasiliy Victorovich Vlassov; Stein Emil Vollset; Elisabete Weiderpass; Hywel C Williams; Nigus Bililign Yimer; Naohiro Yonemoto; Mustafa Z Younis; Christopher J L Murray; Mohsen Naghavi
Journal:  JAMA Oncol       Date:  2018-11-01       Impact factor: 31.777

View more
  1 in total

1.  Antitumorigenic Effect of Tramadol and Synergistic Effect With Doxorubicin in Human Breast Cancer Cells.

Authors:  Yi-Hsuan Huang; Sung-How Sue; Zih-Syuan Wu; Shih-Ming Huang; Shih-Yu Lee; Zhi-Fu Wu
Journal:  Front Oncol       Date:  2022-01-26       Impact factor: 6.244

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.